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Background: Tobacco smoking, a risk factor for coronary artery disease (CAD), is known to modify DNA
methylation. We hypothesized that tobacco smoking modifies methylation of the genes identified for CAD by
genome-wide association study (GWAS).
Results: We selected genomic regions based on 150 single-nucleotide polymorphisms (SNPs) identified in the
largest GWAS on CAD. We investigated the association between current smoking and the CpG sites within and near
these CAD-related genes. Methylation was measured with the Illumina Human Methylation 450K array in whole
blood of 724 Caucasian subjects from the Rotterdam Study, a Dutch population based cohort study.
A total of 3669 CpG sites within 169 CAD-related genes were studied for association with current compared to never
smoking. Fifteen CpG sites were significantly associated after correction for multiple testing (Bonferroni-corrected
p value <1.4 × 10−5). These sites were located in the genes TERT, SARS, GNGT2, SMG6, SKI, TOM1L2, SIPA1, MRAS, CDKN1A,
LRRC2, FES and RPH3A. In 12 sites, current smoking was associated with a 1.2 to 2.4 % lower methylation compared to
never smoking; and in three sites, it was associated with a 1.2 to 1.8 % higher methylation. The effect estimates were
lower in 10 of the 15 CpG sites when comparing current to former smoking. One CpG site, cg05603985 (SKI), was found
to be associated with expression of nearby CAD-related gene PRKCZ.
Conclusions: Our study suggests an effect of tobacco smoking on DNA methylation of CAD-related genes and thus
provides novel insights in the pathways that link tobacco smoking to risk of CAD.
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In recent years, large genome-wide association studies
(GWAS) have been conducted to identify genetic risk
factors for a vast amount of diseases including coronary
artery disease (CAD). These GWAS have successfully
identified tens of single-nucleotide polymorphisms
(SNPs) located in genes and their vicinity that might
play a role in the pathophysiology of CAD. The CARDI-
oGRAMplusC4D consortium is the largest CAD-GWAS
consortium comprising 63,746 CAD cases and 130,681
controls [1]. This consortium has found 46 susceptibility
loci significantly associated with the risk of CAD and
104 loci suggestive for CAD (FDR < 0.05).* Correspondence: a.dehghan@erasmusmc.nl
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unless otherwise stated.One of the major risk factors for CAD is tobacco smok-
ing which accounts for 10–15 % of the risk [2]. Recent
studies have shown that smoking can interact with genetic
variation to increase the risk of CAD [3, 4]. One of the po-
tential mechanisms for this interaction is DNA methyla-
tion. DNA methylation is the attachment of a methyl
group to a nucleotide which occurs most often at the
cytosine nucleotide of CpG dinucleotides. Methylation has
varying functions at different locations in the human gen-
ome including influence on gene expression [5].
Since studies have established an important role for
smoking in DNA methylation [6–8], we hypothesized
that tobacco smoking changes DNA methylation of
genes in/near loci identified for CAD, which in turn
could alter gene expression of these genes. We therefore
investigated the association between DNA methylation
of genes in/near CAD-GWAS loci in whole blood and
tobacco smoking in the Rotterdam Study. Furthermore,ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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expression of CAD-related genes nearby the identified
differentially methylated sites.
Results
Characteristics of the participants under study are summa-
rized in Table 1. Of the 724 subjects in the study, 195 were
current smokers and 201 were never smokers. The mean
age was 59.9 years. Among the current smokers, 50 % was
male, among the never smoker 37 % (p = 0.008).
The 150 SNPs identified in the CAD GWAS were anno-
tated to 85 genes with an in-gene variant and 84 cis-
expression-quantitative trait loci (cis-eQTL) within 1 Mb
of the identified SNPs as found in a large publically avail-
able blood cis-eQTL database (FDR < 0.05) (Additional
file 1: Table S1) [9]. These genes had 3669 methylation
sites measured on the array within and near the gene as
provided by Illumina (Additional file 1: Table S2). After
correction for multiple testing, 15 CpG sites were signifi-
cantly associated with current smoking (p < 1.4 × 10−5)
(Table 2). Current tobacco smoking was associated with a
1.2 to 2.4 % lower DNA methylation compared to never
smoking in 12 of the CpG sites. In three CpG sites,
current tobacco smoking was associated with a 1.2 to 1.8Table 1 Characteristics of study population
Total Current smo
N 724 195
Age (years) 59.9 (8.2) 58.1 (6.7)
Sex (male) 334 (46 %) 98 (50 %)
BMI (kg/m2) 27.6 (4.6) 26.8 (4.3)
Proportion CD8+ T-cellsb 0.09 (0.05) 0.10 (0.05)
Proportion CD4+ T-cellsb 0.26 (0.08) 0.27 (0.07)
Proportion NK cellsb 0.14 (0.06) 0.11 (0.06)
Proportion B-cellsb 0.10 (0.04) 0.10 (0.04)
Proportion monocytesb 0.08 (0.03) 0.08 (0.03)
Proportion granulocytesb 0.37 (0.11) 0.38 (0.11)
Nr. erythrocytes (109/L) 4.90 (0.37) 4.86 (0.36)
Nr. platelets (109/L) 283.8 (63.9) 293.2 (69.3)
Fasting (yes)c 717 (99 %) 192 (99 %)
Alcohol (g/day) 18.2 (11.3) 19.3 (12.8)
RNA quality score 8.38 (0.51) 8.36 (0.50)
Type 2 diabetes mellitus 53 (7.3 %) 7 (3.6 %)
Total cholesterol (mmol/L) 5.6 (1.3) 5.6 (1.1)
Triglycerides (mmol/L) 1.49 (0.87) 1.68 (1.14)
Systolic blood pressure (mmHg) 135.7 (61.7) 132.3 (61.7)
Diastolic blood pressure (mmHg) 84.9 (63.3) 83.5 (61.7)
Data are mean (SD) or n (%)
aCurrent versus never
bHouseman-estimated white blood cell proportions
cThe subjects who provided blood in fasting condition% higher DNA methylation. The effect estimates of the as-
sociations were robust to further adjustment for total
cholesterol, triglyceride levels, systolic blood pressure,
daily alcohol intake and type 2 diabetes mellitus as poten-
tial confounders or mediators. In a sensitivity analysis in
current smokers, two sites were significantly associated
with cumulative exposure to tobacco smoking (Table 3).
When comparing current to former smokers, the effect
estimates were lower and the differences were no longer
significant in 10 of the 15 CpG sites (Table 2). This was
confirmed in a sensitivity analysis in former smokers,
which showed that cessation time was associated with dif-
ferences in methylation level in three of the identified
CpG sites (Table 3).
The two top CpG sites, cg24908166 and cg12324353,
were annotated to TERT (Table 4). The two CpG sites
were positively correlated with each other (r = 0.27, p <
0.001) and were located within 1 kb from each other in an
intron of TERT. Two other CpG sites cg05603985 and
cg09469355 were located within 1 kb from each other in
the first exon and intron of SKI. Methylation of these two
sites was positively correlated (r = 0.57, p < 0.001). CpG
sites cg09397246 and cg26405020 were located within
1500 base pairs from the transcription start site of FES.kers Former smokers Never smokers p-valuea
319 210
61.5 (8.6) 59.2 (8.4) 0.15
155 (49 %) 78 (37 %) 0.008
28.0 (4.5) 27.7 (4.9) 0.05
0.09 (0.06) 0.10 (0.05) 0.81
0.26 (0.08) 0.26 (0.08) 0.33
0.14 (0.06) 0.14 (0.06) <0.001
0.10 (0.03) 0.10 (0.04) 0.59
0.08 (0.03) 0.08 (0.03) 0.55
0.37 (0.12) 0.37 (0.11) 0.12
4.93 (0.37) 4.88 (0.38) 0.67
280.2 (61.0) 280.4 (62.4) 0.05
315 (99 %) 210 (100 %) 0.07
18.9 (11.5) 16.0 (8.9) 0.002
8.39 (0.49) 8.38 (0.54) 0.66
34 (10.6 %) 12 (5.7 %) 0.31
5.6 (1.5) 5.6 (1.1) 0.88
1.43 (0.68) 1.39 (0.80) 0.005
137.5 (64.3) 136.3 (57.6) 0.50
85.6 (66.7) 85.1 (59.7) 0.79
Table 2 Significant associations between tobacco smoking and methylation of CAD genes
Current-Never Adjusted model Current-Former Adjusted model
CpG site Estimate (se) p-value Estimate (se) p-value Estimate (se) p-value Estimate (se) p-value
cg24908166 −0.014 (0.003) 1.1 × 10−7 −0.015 (0.003) 1.6 × 10−8 −0.006 (0.002) 0.02 −0.007 (0.003) 0.01
cg12324353 −0.012 (0.003) 1.3 × 10−7 −0.012 (0.002) 3.5 × 10−7 −0.007 (0.002) 2.8 × 10−3 −0.007 (0.002) 2.1 × 10−3
cg03725309 −0.024 (0.005) 2.0 × 10−7 −0.022 (0.005) 3.8 × 10−6 −0.017 (0.004) 4.2 × 10−5 −0.016 (0.004) 1.2 × 10−4
cg00980784 −0.015 (0.003) 2.5 × 10−7 −0.014 (0.003) 3.5 × 10−6 −0.015 (0.003) 2.4 × 10−8 −0.015 (0.003) 8.6 × 10−8
cg13916835 −0.021 (0.004) 3.0 × 10−7 −0.021 (0.004) 1.3 × 10−6 −0.013 (0.004) 1.5 × 10−3 −0.013 (0.004) 1.9 × 10−3
cg09469355 −0.017 (0.003) 7.7 × 10−7 −0.017 (0.003) 8.5 × 10−7 −0.015 (0.003) 3.8 × 10−6 −0.015 (0.003) 1.6 × 10−6
cg05603985 −0.014 (0.003) 8.4 × 10−7 −0.013 (0.003) 3.6 × 10−5 −0.014 (0.003) 1.3 × 10−7 −0.014 (0.003) 2.4 × 10−7
cg04324276 −0.015 (0.003) 3.2 × 10−6 −0.015 (0.003) 1.2 × 10−5 −0.010 (0.003) 2.4 × 10−4 −0.010 (0.003) 5.2 × 10−4
cg25468516 −0.015 (0.003) 3.6 × 10−6 −0.014 (0.003) 3.0 × 10−5 0.011 (0.003) 2.3 × 10−4 0.012 (0.003) 1.2 × 10−4
cg22907952 −0.011 (0.002) 4.5 × 10−6 −0.010 (0.003) 6.9 × 10−5 −0.007 (0.002) 1.1 × 10−3 −0.007 (0.002) 1.5 × 10−3
cg15474579 −0.017 (0.004) 5.0 × 10−6 −0.013 (0.004) 5.2 × 10−4 −0.016 (0.003) 2.0 × 10−6 −0.016 (0.003) 7.6 × 10−6
cg20496896 0.012 (0.003) 6.7 × 10−6 0.013 (0.003) 4.6 × 10−6 0.005 (0.002) 0.06 0.005 (0.002) 0.03
cg09397246 0.018 (0.004) 1.0 × 10−5 0.018 (0.004) 3.1 × 10−5 0.017 (0.003) 5.6 × 10−7 0.017 (0.003) 1.9 × 10−6
cg26405020 0.014 (0.003) 1.2 × 10−5 0.014 (0.003) 1.4 × 10−5 0.008 (0.003) 2.6 × 10−3 0.007 (0.003) 8.2 × 10−3
cg18236066 −0.014 (0.003) 1.3 × 10−5 −0.015 (0.003) 2.5 × 10−5 −0.011 (0.003) 1.4 × 10−4 −0.011 (0.003) 1.8 × 10−4
Bonferroni-corrected threshold 1.4 × 10−5
Current-Never: adjusted for age, sex, BMI, Houseman estimates, batch effects
Adjusted model: current-never, adjusted for age, sex, BMI, Houseman estimates, batch effects, systolic blood pressure, total cholesterol, triglycerides, daily alcohol
intake, type 2 diabetes mellitus
Current-Former: adjusted for age, sex, BMI, Houseman estimates, batch effects
Adjusted model: current-former, adjusted for age, sex, BMI, Houseman estimates, batch effects, systolic blood pressure, total cholesterol, triglycerides, daily alcohol
intake, type 2 diabetes mellitus
Table 3 Association between packyears and cessation time and
methylation of significant CpG sites
Packyearsa Cessation timeb
CpG site Estimate (se) p-value Estimate (se) p-value
cg24908166 −0.001 (0.001) 0.24 −0.003 (0.001) 0.02
cg12324353 −0.003 (0.001) 2.3 × 10−3 0.002 (0.001) 0.05
cg03725309 −0.002 (0.002) 0.15 0.004 (0.002) 0.02
cg00980784 −0.003 (0.001) 0.01 −0.001 (0.001) 0.69
cg13916835 −0.002 (0.002) 0.14 0.002 (0.002) 0.24
cg09469355 −0.003 (0.001) 0.04 −0.006 (0.001) 6.0 × 10−5
cg05603985 −0.002 (0.001) 0.03 0.004 (0.001) 1.2 × 10−3
cg04324276 −0.002 (0.001) 0.22 0.002 (0.001) 0.17
cg25468516 −0.001 (0.001) 0.20 0.003 (0.001) 0.06
cg22907952 −0.003 (0.001) 1.8 × 10−3 0.002 (0.001) 0.12
cg15474579 −0.004 (0.001) 0.02 0.005 (0.001) 1.5 × 10−3
cg20496896 0.002 (0.002) 0.12 −0.003 (0.001) 3.9 × 10−3
cg09397246 0.001 (0.002) 0.35 −0.001 (0.002) 0.38
cg26405020 0.002 (0.001) 0.06 −0.002 (0.001) 0.05
cg18236066 −0.002 (0.001) 0.18 0.003 (0.001) 0.04
Bonferroni-corrected threshold 3.3 × 10−3
aIn current smokers, per 10 packyears, adjusted for age, sex, BMI, Houseman
estimates, batch effects
bIn former smokers, per 10 years of smoking cessation, adjusted for age, sex,
BMI, Houseman estimates, batch effects
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and had a positive correlation (r = 0.88, p < 0.001). The
other significant hits were annotated to SARS, GNGT2,
SMG6, TOM1L2, SIPA1, MRAS, CDKN1A, LRRC2 and
RPH3A. The beta-value distributions for all identified
CpG sites stratified by the three smoking categories can
be found in Additional file 2: Figure S1.
The associations between the 15 CpG sites and mRNA
expression of nearby CAD genes are shown in Additional
file 1: Table S3. Increased methylation of cg05603985 (SKI)
was associated with increased expression of cis-eQTL gene
PRKCZ (estimate = 0.035, p = 1.4 × 10−4) (Additional file 1:
Table S3 and Additional file 2: Figure S2). In the mediation
analysis, we did not find a significant proportion of the as-
sociation between tobacco smoking and expression of
PRKCZ to be mediated by methylation of cg05603985 (pro-
portion mediated = 0.24, p = 0.79). The other CpG sites
were not associated with gene expression.Discussion
The results of the current study suggest an association
between tobacco smoking and DNA methylation of 12
genes suggested to be associated to CAD via GWAS.
One of these CpG sites was found to be associated with
expression of nearby CAD-related gene PRKCZ (protein
kinase C, zeta).
Table 4 Characteristics of significant CpG sites
Average beta-values (SD)
CpG site Gene Positiona Placement Current smokers Former smokers Never smokers
cg24908166 TERT 5:1,268,800 Body 0.893 (0.031) 0.900 (0.029) 0.908 (0.024)
cg12324353 TERT 5:1,269,197 Body 0.846 (0.027) 0.851 (0.027) 0.855 (0.024)
cg03725309 SARS 1:109,757,585 Body 0.292 (0.057) 0.297 (0.060) 0.311 (0.063)
cg00980784 GNGT2 17:47,287,577 TSS1500 0.331 (0.048) 0.340 (0.048) 0.341 (0.048)
cg13916835 SMG6 17:2,025,181 Body 0.796 (0.049) 0.812 (0.047) 0.822 (0.039)
cg09469355 SKI 1:2,161,886 Body 0.500 (0.041) 0.516 (0.045) 0.520 (0.040)
cg05603985 SKI 1:2,161,049 First exon 0.347 (0.037) 0.362 (0.038) 0.364 (0.037)
cg04324276 TOM1L2 17:17,817,462 Body 0.502 (0.047) 0.502 (0.046) 0.507 (0.047)
cg25468516 SIPA1 11:65,408,028 5′UTR 0.215 (0.048) 0.218 (0.051) 0.226 (0.054)
cg22907952 MRAS 3:138,121,287 3′UTR 0.806 (0.033) 0.809 (0.034) 0.812 (0.030)
cg15474579 CDKN1A 6:36,753,790 Body 0.706 (0.058) 0.718 (0.052) 0.726 (0.047)
cg20496896 LRRC2 3:46,579,532 Body 0.728 (0.056) 0.727 (0.055) 0.712 (0.056)
cg09397246 FES 15:91,427,361 TSS1500 0.296 (0.066) 0.285 (0.065) 0.286 (0.062)
cg26405020 FES 15:91,427,363 TSS1500 0.464 (0.057) 0.459 (0.059) 0.457 (0.055)
cg18236066 RPH3A 12:113,293,823 Body 0.702 (0.040) 0.709 (0.038) 0.713 (0.041)
TSS1500, 1500 base pairs for transcription start sites
aBased on genome build 37
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tween current and former smokers was lower compared
to the difference between current and never smokers in
10 of the 15 CpG sites. This suggests that the effect of
tobacco smoking on DNA methylation of these CpG
sites is relatively sustained after smoking cessation. To
explore the time needed for these CpG sites to recover,
we did an analysis on methylation and cessation time
and found that cessation time was associated with DNA
methylation in 3 of the 15 CpG sites. These results are
in line with findings from a recent paper on the relation
between tobacco smoking cessation and DNA methyla-
tion [6]. We further found that 2 of the 15 CpG sites
were associated with cumulative tobacco smoking expos-
ure in current smokers, which is concordant with results
from previous studies [6, 7].
The top two CpG sites, cg24908166 and cg12324353,
are located within TERT (telomerase reverse transcript-
ase). High levels of TERT expression are found in mac-
rophages of human atherosclerotic lesions [10]. Two
other CpG sites, cg09397246 and cg26405020, were lo-
cated near the transcription start site of FES (FES proto-
oncogene, tyrosine kinase), which has been identified by
GWAS to be associated with blood pressure and hyper-
tension [11]. Smoking was further associated with methy-
lation of cg09469355 and cg05603985 within SKI (avian
sarcoma viral oncogene homolog) which is a repressor of
TGF-beta activity. Decreased TGF-beta activity is associ-
ated with atherosclerosis development and plaque instabil-
ity [12, 13]. This could be a plausible pathway throughwhich smoking can increase the occurrence of CAD since
smoking has already been associated with decreased
plasma levels of TGF-beta and decreased expression of
TGF-beta in bronchial cell lines [14, 15].
PRKCZ might be the functional gene for rs10797416,
the most significant SNP of this locus reported in CAD-
GWAS. Rs10797416 has a cis-eQTL effect on PRKCZ.
PRKCZ is involved in proliferation, differentiation and
secretion of almost all cell types including cardiac myo-
cytes and has been associated with cardiomyopathy in
chromosome 1p36 deletions [16, 17]. We found that to-
bacco smoking is associated with decreased methylation
of cg05603985, which is in turn associated with de-
creased expression of PRKCZ. We propose that demeth-
ylation of cg05603985 might be involved in development
of CAD through PRKCZ expression, although the caus-
ality and mechanism through which this might occur are
unclear. Cg05603985 is located in the binding site of
transcriptional repressor CTCF [ENCODE:GSM1022677,
UW, HCM] [18]. Demethylation of this CTCF binding
site facilitates binding of CTCF, resulting in decreased
expression of PRKCZ. This is due to the fact that CTCF
prevents the binding of enhancers to the promoter of
PRKCZ [19].
None of the other CpG sites was associated with the ex-
pression of nearby CAD-related genes. The lack of an as-
sociation does not necessarily mean that methylation of
these sites has no effect on expression but could result
from an insufficient statistical power. This also applies
for the non-significant mediation analysis. Furthermore,
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may therefore not be found in whole blood. In addition,
not all methylation sites in the human genome have an ef-
fect on mRNA expression. It could be that these methyla-
tion sites function through histone modification or DNA
stability which could not be studied in the current work.
Finally, it could be that these sites are merely biomarkers
of tobacco smoking [5].
The availability of DNA methylation and mRNA ex-
pression data from the same samples is a major strength
of this study. Therefore, we were able to conduct an in-
depth exploration of the association between smoking,
DNA methylation and mRNA expression of CAD-
related genes. Our study involved methylation and ex-
pression data from whole blood samples and not from
vascular or lung tissue. This could be a limitation, since
methylation and expression might be tissue specific.
However, the relationship between smoking and DNA
methylation has been confirmed in other tissues includ-
ing lung tissue [20]. Furthermore, in a study of athero-
sclerotic tissue, three of our identified genes (PRKCZ,
LCCR2 and SMG6) were found to be differentially meth-
ylated [21]. This provides further evidence that our find-
ings may be influential in the atherosclerotic pathway.
However, this needs further investigation in functional
studies. A second limitation is the challenge of gene anno-
tation in GWAS. GWAS locate risk variants for the
phenotype under study, but the underlying causal gene
might be difficult to designate. To minimize this prob-
lem, we limited our analysis to in-gene variants and
variants with known cis-eQTL effects. Therefore, the
CAD-related genes in our study are more plausible to
be actual causal variants for CAD, thus making the re-
sults more convincing.
Conclusions
Our study provides examples of CAD-related genes of
which differential methylation is associated with tobacco
smoking. Whether or not these genes are in the causal
pathway between smoking and coronary artery disease




The study was conducted using data from the third cohort
of the Rotterdam Study. The design of the Rotterdam
Study has previously been described elsewhere [22]. Briefly,
all inhabitants from the neighbourhood Ommoord in
Rotterdam aged 45 years and over were invited to par-
ticipate. During the centre visit, 3934 participants were
examined between February 2006 and December 2008.
We performed the analyses on a random subset of 747
Caucasian subjects from the centre visit. The study wasapproved by the medical ethics committee at Erasmus
University Rotterdam, Rotterdam, the Netherlands, and all
examined participants gave written informed consent.
Data collection
Data on tobacco smoking was collected during home in-
terviews. Participants were asked about past and present
cigarette, cigar and pipe smoking behaviour and were
then categorized into current, former and never tobacco
smokers. Furthermore, information on starting age of
smoking, stopping age and time of discontinuation were
used to determine packyears in current smokers (median
25.6 packyears, interquartile range 11.4 to 38.0) and cessa-
tion time in former smokers (median 21.5 years, in-
terquartile range 10.6 to 32.6). Seven participants had
missing smoking status and were therefore excluded from
any analysis. During the centre visit, weight and height
were measured in standing position wearing normal
cloths. All participants had blood samples taken during
the visit to quantify DNA methylation, messenger RNA
(mRNA) expression levels and other blood measurements.
DNA methylation data
DNA was extracted from whole peripheral blood (stored
in EDTA tubes) by standardized salting out methods.
Genome-wide DNA methylation levels were measured
using Illumina Human Methylation 450K array [23]. In
short, samples (500 ng of DNA per sample) were first bi-
sulfite treated using the Zymo EZ-96 DNA-methylation
kit (Zymo Research, Irvine, CA, USA). Next, they were
hybridized to the arrays according to the manufacturer’s
protocol. The methylation percentage of a CpG site was
reported as a beta-value ranging between 0 (no methyla-
tion) and 1 (full methylation).
Quality control of the samples was done with Genome
Studio. A total number of 16 samples were removed:
seven had a sample call rate below 99 %; five had incom-
plete bisulfite conversion and four had gender swaps.
Quality control of the probes was done based on the de-
tection p-value calculated with Genome Studio. Probes
with a detection p-value of more than 0.01 in more than
1 % of the samples were excluded. This resulted in a
total set of 474,528 probes which were normalized using
the Dasen option of the WateRmelon R-package [24].
mRNA expression data
Whole-blood was collected (PAXGene Tubes - Becton
Dickinson), and total RNA was isolated (PAXGene
Blood RNA kits - Qiagen). To ensure a constant high
quality of the RNA preparations, all RNA samples were
analysed using the Labchip GX (Calliper) according to
the manufacturer’s instructions. Samples with an RNA
quality score more than 7 were amplified and labelled
(Ambion TotalPrep RNA) and hybridized to the Illumina
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manufacturer’s protocol. Processing of the Rotterdam
Study RNA samples was performed at the Genetic La-
boratory of Internal Medicine, Erasmus University Med-
ical Centre Rotterdam. The RS-III expression dataset is
available at GEO (Gene Expression Omnibus) public re-
pository under the accession GSE33828: 881 samples are
available for analysis.
Illumina gene expression data was quantile normalized
to the median distribution and subsequently log2 trans-
formed. The probe and sample means were centred to
zero. Genes were declared significantly expressed when
the detection p-values calculated by Genome Studio were
less than 0.05 in more than 10 % of all discovery samples,
which added to a total number of 21,238 probes. Quality
control was done using the eQTL mapping pipeline.
Statistical analysis
The characteristics of the study population were com-
pared between current and never smokers using IBM
SPSS Statistics version 21.0.0.1 (IBM Corp.). The p-values
were calculated using independent sample T-test for con-
tinuous variables and chi-square test for dichotomous
variables.
Of the 150 SNPs discovered by CARDIoGRAM-
plusC4D, 96 were located within a gene [1]. In addition,
58 SNPs had known effect on expression of a gene
within 1 Mb as found in a large publically available
blood cis-eQTL database (FDR < 0.05) [9]. We anno-
tated these SNPs to 85 genes with an in-gene variant
and 84 cis-eQTL genes (Additional file 1: Table S1). The
methylation probes within and near these CAD-related
genes as provided by Illumina were included in the ana-
lysis. We excluded probes from the Infinium HD methy-
lation SNP list with a minor allele frequency above 1 %
as provided by Illumina, since variations in these SNPs
can cause bias in the methylation measurement [25]. We
further excluded known cross-reactive probes, since they
can introduce bias in the results [26]. A complete list of
the probes considered for analysis including reasons for
exclusion can be found in Additional file 1: Table S2.
The remaining 3669 methylation probes were checked
for association with tobacco smoking using a linear
mixed model with the LME4 package in R version 3.1.0
with Dasen normalized beta-values of the CpG sites as
outcome measure [27]. We first compared current to
never smokers and then performed a sensitivity analysis
on the identified CpG sites comparing current to former
smokers. Covariates were selected based on known asso-
ciation with DNA methylation and different distributions
between current and never smokers in our samples. The
selected covariates with fixed effects were age, sex and
BMI [28–31]. Houseman estimated white blood cell pro-
portions were used as fixed effects to correct for cellmixture distribution [32]. Array number and position on
array were added in the model as covariates with ran-
dom effects to correct for batch effects. We corrected
for multiple testing using a robust Bonferroni-corrected
p-value of 1.4 × 10−5 as the threshold for significance
(0.05/3669 probes).
To decrease the possibility of confounding in our asso-
ciation, we further adjusted the model in a second ana-
lysis for other possible confounders and mediators. This
analysis included total cholesterol, triglyceride levels,
systolic blood pressure, daily alcohol intake and type 2
diabetes mellitus.
To assess the effect of cumulative exposure to tobacco
smoking on DNA methylation, we performed a sensitivity
analysis on the identified CpG sites in current smokers
with packyears per 10 year as exposure. To assess the ef-
fect of discontinuation of tobacco smoking exposure, we
performed a sensitivity analysis on the identified CpG sites
in former smokers using cessation time per 10 years as ex-
posure. The robust Bonferroni-corrected p-value for both
analyses was 3.3 × 10−3 (0.05/15).
Functional analysis
Since DNA methylation may have an effect on gene ex-
pression, we tested the association between DNA methy-
lation and mRNA expression of nearby CAD-related
genes. In the 724 individuals under study, 16 genes out
of 26 candidates were found to be expressed in blood.
First, we regressed out the Houseman-estimated white
blood cell proportions, the erythrocytes and platelet cell
counts, fasting state, RNA quality score, plate number,
age and sex on the mRNA expression levels using a lin-
ear mixed model. We then regressed out the Houseman-
estimated white blood cell proportions, age, sex, array
number and position on array on the Dasen normalized
beta-values of the CpG sites using a linear mixed model.
The residuals of the mRNA expression levels and the re-
siduals of the Dasen normalized beta-values of the CpG
sites were checked for association using a linear regression
model. We analysed the associations between the 15
methylation sites and 16 nearby CAD genes. Additional
file 1: Table S3 indicates the 35 CpG-gene combinations
that were tested. The robust Bonferroni-corrected p-value
threshold for a significant association was 1.4 × 10−3
(0.05/35 tests). Significant associations were reviewed in a
mediation analysis with current versus never smoking as
exposure, Dasen normalized beta-values of the CpG site
as potential mediator and mRNA expression levels as out-
come using the mediation package in R [33]. The method
applied in the mediation package calculates the proportion
of the association between tobacco smoking and expres-
sion that is mediated by methylation. This is done by com-
paring the effect estimates of tobacco smoking on
expression in subjects with different levels of methylation.
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Additional file 1: Tables S1 to S3 Table S1. List of
CARDIoGRAMplusC4D SNPs and annotated in-gene variants and cis-eQTL
genes. Table S2. List of considered CpG sites in/near CAD and cis-eQTL
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of significant CpG sites and expression of nearby CAD-related genes.
Additional file 2: Figure S1 and S2 Figure S1. Beta-value distributions
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